Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision facing companies developing biologics products, such as cell and gene therapies, where technologies are...more
11/15/2024
/ Biologics ,
Business Model ,
Damages ,
Discovery ,
Food and Drug Administration (FDA) ,
Healthcare ,
Injunctive Relief ,
Life Sciences ,
Non-Disclosure Agreement ,
Patent Infringement ,
Patent-Eligible Subject Matter ,
Patents ,
Reverse Engineering ,
Trade Secrets
On July 29, 2022, the U.S. Patent and Trademark Office (USPTO) issued a Notice in the Federal Register clarifying the duty of disclosure that may keep patent practitioners up at night. The Notice reminds applicants of the...more
Patent term extension (PTE) provides additional patent term for patents related to U.S. pharmaceutical products to compensate for the effective loss of patent term caused by delay during the drug approval process by the U.S....more